Skip to content

Comprehensive Optimization At-time of Radical Cystectomy Intervention

Comprehensive Optimization At-time of Radical Cystectomy Intervention Through Peri-operative Patient Care Program

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05714826
Acronym
COARC
Enrollment
0
Registered
2023-02-06
Start date
2026-05-01
Completion date
2026-08-24
Last updated
2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Radical Cystectomy

Keywords

Peri-operative

Brief summary

The proposed study is aimed at a comprehensive optimization at-time of radical cystectomy (COARC) intervention that focuses on patient optimization throughout the perioperative continuum, from the pre-operative setting to the post-operative period, among patients undergoing radical cystectomy for bladder cancer. This multi-modal strategy will focus on three phases of care around surgery: the pre-operative, peri-operative, and post-operative phases. The intervention group will focus on multiple areas of patient optimization including remote patient monitoring for the earlier identification of potential complications. The overall study mission is to decrease complication rates after radical cystectomy using this comprehensive approach.

Detailed description

The proposed study includes the following- Part I: Pre-operative period After randomization, patients in the intervention group will be referred to the Perioperative Optimization of Senior Health (POSH) program where they will undergo nutritional, functional, and global health assessment. The POSH team will refer patients as indicated to nutrition, physical medicine and rehabilitation, and other consultants to optimize their preoperative fitness for surgery. Patients in the intervention group will also receive a Remote Patient Monitoring (RPM) Ipad from ActiCare Health, which will serve as their remote monitoring device and educational tool. At enrollment, they will be asked to complete an initial steps intake using a pedometer that will be provided to them. They will be asked to input vital signs once per week after receiving the Ipad to become familiar with the platform pre-operatively. At enrollment, patients in both groups will also be asked to complete a patient reported Bladder Cancer Index questionnaire, a survey that tracks quality of life in patients with bladder cancer. Part II: Perioperative period Both the intervention and control groups will undergo standard of care Enhanced Recover After Surgery (ERAS) bladder cancer protocol, which is a medication and peri-operative management protocol developed by the anesthesia and urology departments specifically for bladder cancer patients undergoing radical cystectomy. While admitted in the hospital recovering from surgery, patients in the intervention group will automatically receive co-management from the POSH team. Part III: Post-operative period Both the intervention and the control groups will be followed for 90 days post-operatively. The intervention group will use the RPM Ipad to input vital signs, weight, and pedometer steps 3x/week and on an as needed basis over the follow-up period which will be monitored by the ActiCare Health 24/7 clinical support team. Abnormal parameters will be set so that the UT Southwestern Medical Center clinical care team is alerted to any abnormal values.

Interventions

OTHERPreop Intervention and Monitored Recovery

Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care

OTHERUsual Care

ERAS, Usual referral and recovery care, and Standard follow-up protocol

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

It is a prospective randomized study that implements a multi-modal digitally based comprehensive health optimization program in the pre and post-operative setting in patients undergoing radical cystectomy for muscle invasive bladder cancer. Two patient groups will be enrolled and randomized where one group will go through the peri-operative optimization programs and the other group will receive the usual pre-op care followed by post-op care via standard follow-up protocol.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults equal to or more than 18 years old * Diagnosis of bladder cancer with plan to undergo radical cystectomy * Agrees to participate in study procedures

Exclusion criteria

* Patients undergoing cystectomy for diagnosis other than bladder cancer * Do not provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
90 day complication rate90 daysNumber of occurrences of complications at 90 days in patients in post-operative phase

Secondary

MeasureTime frameDescription
30 day complication rate30 daysNumber of occurrences of complications at 30 days in patients in post-operative phase
Readmission rates90 daysNumber of readmissions
Adherence to the intervention90 daysIt is assessed via patient-self report measure
Changes in functional fitness as measured by step countBaseline, 90 daysChanges in functional fitness will be measured by step count
QOL changes as measured by the Bladder Cancer Index and FACT-Bl-Cys Questionnaire measuresBaseline, 90 daysChanges in patient reported outcomes will be measured by QOL (Bladder Cancer Index questionnaire). Possible scores range from 0-100, where higher scores indicate better HRQOL outcome. Changes will also be measured using the FACT-Bl-Cys tool to assess changes in bladder related quality of life in patients undergoing cystectomy over the course of the study.

Contacts

PRINCIPAL_INVESTIGATORYair Lotan, MD

University of Texas Southwestern Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026